title: Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
abstract: Serum samples from Alzheimer's disease (AD) patients immunized with Abeta42 (AN1792) were analyzed to determine the induced antibody properties including precise amyloid-beta peptide (Abeta) epitopes and amyloid plaque-binding characteristics. The predominant response in these patients is independent of whether or not meningoencephalitis developed and is against the free amino terminus of Abeta. The immunostaining of amyloid plaques in brain tissue by patient sera is adsorbable by a linear Abeta1-8 peptide, demonstrating that the antibodies are directed predominantly to this epitope and not dependent on Abeta conformations or aggregates specific to plaques. Furthermore, the antibodies are not capable of binding amyloid precursor protein and would be predicted to be competent in facilitating clearance of amyloid plaques in AD brains.
authors.affiliation: Elan Pharmaceuticals, Inc., So. San Francisco, CA 94080, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Lee
authors.forename: Frederique
authors.initials: F
authors.lastname: Bard
authors.forename: Kelly
authors.initials: K
authors.lastname: Johnson-Wood
authors.forename: Celeste
authors.initials: C
authors.lastname: Lee
authors.forename: Kang
authors.initials: K
authors.lastname: Hu
authors.forename: Sue G
authors.initials: SG
authors.lastname: Griffith
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Black
authors.forename: Dale
authors.initials: D
authors.lastname: Schenk
authors.forename: Peter
authors.initials: P
authors.lastname: Seubert
mesh_terms: D000544:Alzheimer Disease / Q000276:immunology / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000008:administration & dosage* / Q000276:immunology* / Q000378:metabolism; D000918:Antibody Specificity; D015153:Blotting, Western / Q000379:methods; D004306:Dose-Response Relationship, Immunologic; D018604:Epitope Mapping; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D007114:Immunization / Q000009:adverse effects / Q000379:methods*; D007150:Immunohistochemistry / Q000379:methods; D008590:Meningoencephalitis / Q000097:blood / Q000209:etiology / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology* / Q000378:metabolism
chemical_list: C437846:AN-1792; D016229:Amyloid beta-Peptides; D000939:Epitopes; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)